BRCA2 and mismatch repair cancer syndrome 1: We believe that our results showing frequent BRCA2, EGFR, and NTRK mutations in MSI-H CRC patients, and potentially other cancers with mismatch repair deficiency, offer immediate novel personalized medicine strategies to treat the patients with advanced disease who may have no remaining treatment options.